Investigating late reperfusion therapy for heart attack patients
Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
This study is testing if heart attack patients who arrive at the hospital more than 12 hours after their symptoms start can benefit from a certain heart procedure to improve their recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Locations | 1 site (Copenhagen, Capital Region) |
| Trial ID | NCT02445885 on ClinicalTrials.gov |
What this trial studies
This study examines whether patients with ST-segment elevation myocardial infarction (STEMI) who present more than 12 hours after symptom onset can benefit from acute percutaneous coronary intervention (PCI) compared to delayed PCI. The research focuses on patients who are clinically stable and have experienced symptoms for 12 to 36 hours. By utilizing magnetic resonance imaging to evaluate the final salvage index, the study aims to determine if extending the time limit for acute PCI could improve outcomes for late presenters. The findings could potentially redefine treatment protocols for this patient population.
Who should consider this trial
Good fit: Ideal candidates are patients over 18 years old with STEMI symptoms lasting between 12 and 36 hours who are clinically stable.
Not a fit: Patients who are clinically unstable or have conditions requiring immediate invasive strategies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide evidence to support the use of acute PCI in late presenters, potentially improving their cardiac outcomes.
How similar studies have performed: While the approach of investigating late PCI is less common, similar studies have shown varying results, indicating that this area remains underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion criteria: * Patients more than 18 years of age. * STEMI \> 12 hours and \< 36 hours. * Clinical stable, i.e. no on going angina, hemodynamically stable (systolic BP \> 90) and Killip class \< 3. Exclusion Criteria: * Clinical instability which requires an acute invasive strategy. * Left main occlusion or multivessel disease which requires CABG. * Previous Q-wave infarction in the current infarct related artery. * Left Bundle Branch Block (LBBB). * Severe renal insufficiency. * Pacemaker * Chronic atrial fibrillation. * Previous Coronary Artery Bypass Surgery (CABG). * Pregnancy. * Other severe illness with life expectancy less than 1 year
Where this trial is running
Copenhagen, Capital Region
- Rigshospitalet — Copenhagen, Capital Region, Denmark (Recruiting)
Study contacts
- Principal investigator: Lars Nepper-Christensen, MD — Rigshospitalet, Denmark
- Study coordinator: Lars Nepper-Christensen, MD
- Email: lars.nepper@gmail.com
- Phone: +4535457586
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.